Early COVID-19 treatment with Sotrovimab in high-risk Beta-thalassemia: Real-life case-series, state of the art and new perspectives
Corresponding Author
Lorenza Torti
Hemoglobinopathies Unit, Hematology Department, S. Eugenio Hospital (ASL Rome 2), Regional Center for the Diagnosis amd Treatment of Rare Anemias and Disorders of Iron metabolism, Rome, Italy
Correspondence
Lorenza Torti, Hemoglobinopathies Unit, Hematology Department, Sant'Eugenio Hospital, Rome, Italy.
Email: [email protected]
Search for more papers by this authorCorresponding Author
Lorenza Torti
Hemoglobinopathies Unit, Hematology Department, S. Eugenio Hospital (ASL Rome 2), Regional Center for the Diagnosis amd Treatment of Rare Anemias and Disorders of Iron metabolism, Rome, Italy
Correspondence
Lorenza Torti, Hemoglobinopathies Unit, Hematology Department, Sant'Eugenio Hospital, Rome, Italy.
Email: [email protected]
Search for more papers by this author
Open Research
DATA AVAILABILITY STATEMENT
The author guaranteed and vouched for the accuracy and completeness of the data presented. The data that support the findings of this study are available from the corresponding author (L.T.), upon reasonable request.
Supporting Information
| Filename | Description |
|---|---|
| bjh19011-sup-0001-Supinfo.docxWord 2007 document , 12.9 KB |
Table S1. |
| bjh19011-sup-0002-VideoS1.mp4MPEG-4 video, 18.7 MB |
Video S1. |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Cruz-Teran C, Tiruthani K, McSweeney M, Ma A, Pickles R, Lai SK. Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy. Adv Drug Deliv Rev. 2021; 169: 100–117. https://doi.org/10.1016/j.addr.2020.12.004
- 2Bussini L, Testi D, Tazza B, Oltolini C, Mastaglio S, Sepulcri C, et al. Neutralizing monoclonal antibodies for early treatment of hospital-acquired SARS-CoV-2 infection in hematologic patients. EJHaem. 2022; 3(4): 1172–1180. https://doi.org/10.1002/jha2.554
- 3De Sanctis V, Canatan D, Corrons JLV, Karimi M, Daar S, Kattamis C, et al. Preliminary data on COVID-19 in patients with hemoglobinopathies: a multicentre ICET-A study. Mediterr J Hematol Infect Dis. 2020; 12(1):e2020046. https://doi.org/10.4084/MJHID.2020.046
- 4Carsetti R, Agrati C, Pinto VM, Gianesin B, Gamberini R, Fortini M, et al. Premature aging of the immune system affects the response to SARS-CoV-2 mRNA vaccine in β-thalassemia: role of an additional dose. Blood. 2022; 140(15): 1735–1738. https://doi.org/10.1182/blood.2022017594
- 5Farmakis D, Giakoumis A, Cannon L, Angastiniotis M, Eleftheriou A. COVID-19 and thalassaemia: a position statement of the Thalassaemia International Federation. Eur J Haematol. 2020; 105(4): 378–386. https://doi.org/10.1111/ejh.13476
- 6Hu Y, Meng X, Zhang F, Xiang Y, Wang J. The in vitro antiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate co-receptor. Emerg Microbes Infect. 2021; 10(1): 317–330. https://doi.org/10.1080/22221751.2021.1888660
- 7O'Horo J, Challener D, Speicher L, Bosh W, Seville MT, Bierle D, et al. Effectiveness of monoclonal antibodies in preventing severe COVID-19 with emergence of Delta variant. Mayo Clin Proc. 2022; 97(2): 327–332.
- 8Razonable RR, Ganesh R, Bierle DM. Clinical prioritization of Antispike monoclonal antibody treatment of mild to moderate COVID-19. Mayo Clin Proc. 2022; 97(1): 26–30. https://doi.org/10.1016/j.mayocp.2021.11.017
- 9Torti L, Maffei L, Sorrentino F, De Fabritiis P, Miceli R, Abruzzese E. Impact of SARS CoV-2 in hemoglobinopathies with immune disfunction and epidemiology. A protective mechanism from Beta chain hemoglobin defects? Mediterr J Hematol Infect Dis. 2020; 12(1):e2020052. https://doi.org/10.4084/MJHID.2020.052
- 10Torti L, Sorrentino F, Maffei L, De Fabritiis P, Abruzzese E. Epidemiological surveillance of SARSCov2 in β-thalassemia patients in the last two years: reinfection rate, insights and future challenges. Mediterr J Hematol Infect Dis. 2023; 15(1):e2023007. https://doi.org/10.4084/MJHID.2023.007
- 11Chatterjee S, Choudhury S, Das D. An update of antispike severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies. Indian J Pharm. 2022; 54(1): 51–57. https://doi.org/10.4103/ijp.ijp_519_21
- 12Razonable RR, Aloia NCE, Anderson RJ, Anil G, Arndt LL, Arndt RF, et al. A framework for outpatient infusion of Antispike monoclonal antibodies to high-risk patients with mild-to-moderate coronavirus disease-19: the Mayo Clinic Model. Mayo Clin Proc. 2021; 96(5): 1250–1261. https://doi.org/10.1016/j.mayocp.2021.03.010
- 13Ong SWX, Ren D, Lee PH, Sutjipto S, Dugan C, Khoo BY, et al. Real-world use of sotrovimab for pre-emptive treatment in high-risk hospitalized COVID-19 patients: an observational cross-sectional study. Antibiotics (Basel). 2022; 11(3): 345. https://doi.org/10.3390/antibiotics11030345
- 14Tao K, Tzou PL, Kosakovsky Pond SL, Ioannidis JPA, Shafer RW. Susceptibility of SARS-CoV-2 omicron variants to therapeutic monoclonal antibodies: systematic review and meta-analysis. Microbiol Spectr. 2022; 10(4):e0092622. https://doi.org/10.1128/spectrum.00926-22
- 15Huespe I, Carboni Bisso I, Di Stefano S, Terrasa S, Gemelli NA, Las HM. COVID-19 severity index: a predictive score for hospitalized patients. Med Intensiva (Engl Ed). 2022; 46(2): 98–101. https://doi.org/10.1016/j.medine.2020.12.002
- 16Bierle DM, Ganesh R, Tulledge-Scheitel S, Hanson SN, Arndt LL, Wilker CG, et al. Monoclonal antibody treatment of breakthrough COVID-19 in fully vaccinated individuals with high-risk comorbidities. J Infect Dis. 2022; 225(4): 598–602. https://doi.org/10.1093/infdis/jiab570
- 17Cicchitto G, Cardillo L, Sequino D, Sabatini P, Adamo L, Marchitiello R, et al. Effectiveness of Sotrovimab in the omicron storm time: a case series. Viruses. 2022; 15(1): 102. https://doi.org/10.3390/v15010102
